ArticleLKB1 Inactivation Dictates Therapeutic Response of Non-Small Cell Lung Cancer to the Metabolism Drug Phenformin (cas 114-86-3)

Add time:08/29/2019    Source:sciencedirect.com

SummaryThe LKB1 (also called STK11) tumor suppressor is mutationally inactivated in ∼20% of non-small cell lung cancers (NSCLC). LKB1 is the major upstream kinase activating the energy-sensing kinase AMPK, making LKB1-deficient cells unable to appropriately sense metabolic stress. We tested the therapeutic potential of metabolic drugs in NSCLC and identified phenformin, a mitochondrial inhibitor and analog of the diabetes therapeutic metformin, as selectively inducing apoptosis in LKB1-deficient NSCLC cells. Therapeutic trials in Kras-dependent mouse models of NSCLC revealed that tumors with Kras and Lkb1 mutations, but not those with Kras and p53 mutations, showed selective response to phenformin as a single agent, resulting in prolonged survival. This study suggests phenformin as a cancer metabolism-based therapeutic to selectively target LKB1-deficient tumors.

We also recommend Trading Suppliers and Manufacturers of Phenformin (cas 114-86-3). Pls Click Website Link as below: cas 114-86-3 suppliers

Prev:Molecular and Cellular PharmacologyPhenformin (cas 114-86-3) has a direct inhibitory effect on the ATP-sensitive potassium channel
Next:Spectrophotometric determination of OBIDOXIME CHLORIDE (cas 114-90-9) as its Pd(II) complex in water and injections☆)